Don’t miss this story of a patient who refuses to let cancer define his life.  

Join us as we speak to Bruce Rieder, who was diagnosed in 2019 with mantle cell lymphoma (MCL), a type of non-Hodgkin lymphoma. In this episode, Bruce shares about his diagnosis and subsequent search for a clinical trial. He connected with the LLS Clinical Trial Support Center, sought out a second opinion and ended up with a specialist in a nearby cancer center. He received a stem cell transplant in February 2020, right before the world shut down due to COVID.  

Now, two years after his transplant, Bruce stays active in the LLS Community and has received support from the Patti Robinson Kauffman First Connection® program.

Mentioned on this episode: 

• Mantle Cell Lymphoma
• Mantle Cell Lymphoma (MCL) Part One: Treatment Advances episode
• Mantle Cell Lymphoma (MCL) Part Two: CAR T-Cell Therapy episode
• Stem Cell Transplant
• Non-Hodgkin Lymphoma
• COVID Information
• Patti Robinson Kaufmann First Connection Program
• Clinical Trial Support Center
• LLS Community 

Additional LLS Support Resources: 

• Information Specialists
• Financial support
• Free telephone/web patient programs 
• Free booklets 
• LLS Public Policy & Advocacy
• Online chats 
• Caregiver support 
• Support groups 
• Free Nutrition Consultations 
• LLS Advocacy
• Survivorship Workbook

Support for this episode provided by Bristol Myers Squibb, Eli Lilly and Company, Genentech, Inc. & Biogen, and Merck & Co., Inc.

The post Cancer Doesn’t Define My Life: A Non-Hodgkin Lymphoma Story first appeared on The Bloodline with LLS.

Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.

Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by Bristol Myers Squibb; CRISPR Therapeutics; Janssen Oncology & Legend Biotech; KITE, a Gilead Company and Novartis Pharmaceuticals Corporation.

The post Mantle Cell Lymphoma (MCL) Part Two: CAR T-Cell Therapy first appeared on The Bloodline with LLS.

Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.

Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by Eli Lilly & Company.

The post Mantle Cell Lymphoma (MCL) Part One: Treatment Advances first appeared on The Bloodline with LLS.

Join us as we speak to Dr. Caron Jacobson, an Assistant Professor of Medicine at Harvard Medical School and a lymphoma physician and researcher at the Dana-Farber Cancer Institute. In this episode, Dr. Jacobson shares about the use and benefits of CAR T-cell therapy in B-cell cancers, such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). You will hear about how CAR T-cell therapy works, why it is used for B-cell cancers and the benefits of joining a clinical trial for this type of treatment.

Mentioned on this episode:

• CAR T-cell Therapy
• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma
• Chronic Lymphocytic Leukemia
• Immune Effector Cell Therapy Program – Dana-Farber Cancer Institute
• Clinical Trial Support Center

Additional LLS Support Resources:

• Information Specialists 
• Free telephone/web patient programs 
• Free booklets 
• Financial support – **Mantle Cell Lymphoma funding is OPEN** 
• Online chats 
• Caregiver support 
• LLS Community 
• Support groups 
• Patti Robinson Kaufmann First Connection Program 
• Free Nutrition Consultations 

Support for this episode provided by Allogene; Bristol Myers Squibb; CRISPR Therapeutics; Kite, a Gilead Company; Janssen Oncology & Legend Biotech; and Novartis Pharmaceuticals.

The post How CAR T-cell Therapy Gives Hope to Cancer Patients first appeared on The Bloodline with LLS.

Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson.  Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute.  On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.

Mentioned on this episode:

Additional LLS support

Support for this episode provided by Pharmacyclics/Janssen.

The post Mantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should Know first appeared on The Bloodline with LLS.

Listen in as Alicia and Lizette speak with Stan Friedman. Stan is a trial lawyer and mantle cell lymphoma (MCL) survivor from Savannah, Georgia. After receiving abnormal lab work and noticing swollen lymph nodes that his doctor pointed out, Stan was referred to a hematologist/oncologist for a bone marrow biopsy. Join them as Stan describes how he was diagnosed, the initial questions he asked his healthcare team, side effects that were both common and uncommon, the importance of support from those around him, and how he is doing five years later.

DOWNLOAD TRANSCRIPT

Mentioned on this episode:

Additional LLS support resources:

Support for this episode provided by AstraZeneca.

The post My MCL Diagnosis: Stan’s Story first appeared on The Bloodline with LLS.

Join Alicia and Lizette as they speak with Dr. Robert Chen about the treatment of mantle cell lymphoma (MCL). Dr. Chen is a hematologist/oncologist at City of Hope in Duarte, California. On this episode, Dr. Chen explains the different variables taken into consideration when choosing the proper treatment for a MCL patient. He also discusses induction chemotherapy, CAR T-cell therapy, and stem cell transplantation, explaining that although allogeneic transplant is potentially curative, it’s important to understand why it should be approached with caution.

You can listen to our other episode with Dr. Chen about mantle cell lymphoma here.

 Mentioned on this episode:

Additional LLS support resources:

Support for this episode provided by AstraZeneca.

The post Treating Mantle Cell Lymphoma first appeared on The Bloodline with LLS.

With over 60 types of lymphomas, a lymphoma diagnosis can be very confusing.  Listen in as Alicia and Lizette speak with hematologist/oncologist Dr. Robert Chen from City of Hope in Duarte, California about mantle cell lymphoma (MCL). On this episode, they discuss how MCL is diagnosed, indolent vs aggressive lymphomas, and the importance of knowing what to research before attempting to learn about a diagnosis on your own. Dr. Chen also talks about how difficult it was to diagnosis MCL in the past but due to strides made in its molecular path, there has been significant progress in extending survival and improving therapy.

You can listen to our other episode with Dr. Chen about mantle cell lymphoma here.

Mentioned on this episode:

LLS Support Resources:

Support for this episode provided by AstraZeneca.

The post Mantle Cell Lymphoma: Indolent vs Aggressive first appeared on The Bloodline with LLS.